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Summary
Background Data about the global, regional, and country-specific variations in the levels and trends of colorectal 
cancer are required to understand the impact of this disease and the trends in its burden to help policy makers 
allocate resources. Here we provide a status report on the incidence, mortality, and disability caused by colorectal 
cancer in 195 countries and territories between 1990 and 2017.
Methods Vital registration, sample vital registration, verbal autopsy, and cancer registry data were used to generate 
incidence, death, and disability-adjusted life-year (DALY) estimates of colorectal cancer at the global, regional, and 
national levels. We also determined the association between development levels and colorectal cancer age-standardised 
DALY rates, and calculated DALYs attributable to risk factors that had evidence of causation with colorectal cancer. All 
of the estimates are reported as counts and age-standardised rates per 100 000 person-years, with some estimates also 
presented by sex and 5-year age groups.
Findings In 2017, there were 1·8 million (95% UI 1·8–1·9) incident cases of colorectal cancer globally, with an age-
standardised incidence rate of 23·2 (22·7–23·7) per 100 000 person-years that increased by 9·5% (4·5–13·5) between 
1990 and 2017. Globally, colorectal cancer accounted for 896 000 (876 300–915 700) deaths in 2017, with an age-
standardised death rate of 11·5 (11·3–11·8) per 100 000 person-years, which decreased between 1990 and 2017 (–13·5% 
[–18·4 to –10·0]). Colorectal cancer was also responsible for 19·0 million (18·5–19·5) DALYs globally in 2017, with an 
age-standardised rate of 235·7 (229·7–242·0) DALYs per 100 000 person-years, which decreased between 1990 and 
2017 (–14·5% [–20·4 to –10·3]). Slovakia, the Netherlands, and New Zealand had the highest age-standardised 
incidence rates in 2017. Greenland, Hungary, and Slovakia had the highest age-standardised death rates in 2017. 
Numbers of incident cases and deaths were higher among males than females up to the ages of 80–84 years, with the 
highest rates observed in the oldest age group (≥95 years) for both sexes in 2017. There was a non-linear association 
between the Socio-demographic Index and the Healthcare Access and Quality Index and age-standardised DALY 
rates. In 2017, the three largest contributors to DALYs at the global level, for both sexes, were diet low in calcium (20·5% 
[12·9–28·9]), alcohol use (15·2% [12·1–18·3]), and diet low in milk (14·3% [5·1–24·8]).
Interpretation There is substantial global variation in the burden of colorectal cancer. Although the overall colorectal 
cancer age-standardised death rate has been decreasing at the global level, the increasing age-standardised incidence 
rate in most countries poses a major public health challenge across the world. The results of this study could be 
useful for policy makers to carry out cost-effective interventions and to reduce exposure to modifiable risk factors, 
particularly in countries with high incidence or increasing burden.
Funding Bill & Melinda Gates Foundation.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
In 2016, cancer accounted for more than 213 million 
disability-adjusted life-years (DALYs) and 8·9 million 
deaths globally.1,2 The burden of cancer is usually reported 
in aggregated form,1,3 but cancer-specific reports allow a 
more detailed exploration of the problem by providing 
information that is useful for the development and 
evaluation of cancer-specific prevention programmes, 
screening strategies, treatment, and resource allocation. 
An understanding of the geographical and temporal 
trends in colorectal cancer is important because it was 
the second leading cause of death (age-standardised and 
all ages) among cancers globally in 2017 and the 
16th leading cause of death among all diseases and 
injuries.4 Trends in the burden of colorectal cancer have 
been subject to substantial changes across the world 
because of the expansion of screening programmes, with 
wide recommendation of colonoscopy in the late 1990s, 
as well as changes in risk factors associated with 
colorectal cancer.5,6
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Whereas colorectal cancer age-standardised death rates 
have stabilised or declined in many high-income 
countries, which historically had the highest burden of 
colorectal cancer in the world,7 the burden is increasing 
in most low-income and middle-income countries,8 
possibly as a result of ageing populations, urbanisation, 
and increased prevalence of westernised lifestyle risk 
factors, such as alcohol consumption, obesity, smoking, 
and suboptimal diet.9,10 The global burden of colorectal 
cancer attributable to various modifiable risk factors has 
not been described elsewhere and is an important 
estimate to report because it has implications for policy 
making and prevention efforts.
Studies reporting the global burden of colorectal cancer 
have been published previously but have several 
limitations. Specifically, previous estimates reported the 
global burden of colorectal cancer in terms of incidence 
and mortality but did not aim to calculate important 
measures such as years of life lost (YLLs), years lived 
with disability (YLDs), and DALYs.3,7,11–14 Moreover, 
although the burden of colorectal cancer and trends 
associated with this disease have been reported up to 
2018, the temporal trends occur at 4-year or 6-year 
intervals for most countries and 95% uncertainty 
intervals (UIs) have been provided only for the most 
recent global estimates in 2018.7,11–13,15 Finally, the 
association between countries’ development status and 
colorectal cancer burden has previously been described 
using Global Cancer Incidence, Mortality and Prevalence 
(GLOBOCAN) data from only a subset of countries.16 We 
aimed to report the incidence, mortality, and disability 
due to colorectal cancer and its attributable risk factors 
from 1990 to 2017 in 195 countries and territories, by age, 
sex, Socio-demographic Index (SDI; a composite of socio-
demographic factors), and Healthcare Access and Quality 
(HAQ) Index, an indicator of health system performance.
Methods
Overview
This study is part of the Global Burden of Diseases, 
Injuries, and Risk Factors Study (GBD), which covers 
seven super-regions, consisting of 21 regions containing 
195 countries and territories. The most up-to-date 
iteration, GBD 2017, reported estimates for 359 diseases 
and injuries; 282 causes of death; and 84 behavioural, 
environmental and occupational, and metabolic risk 
factors. The general methodology used and updates to 
the methodology have been previously presented in 
GBD 2017 papers.4,17–21 Briefly, the mortality-to-incidence 
ratio (MIR) estimation was updated from GBD 2016, 
with use of the HAQ Index rather than the SDI in the 
data cleaning and modelling process, and the spatio-
temporal Gaussian process regression approach was also 
updated. Covariate inputs for the Cause of Death 
Ensemble model (CODEm) were updated and changed 
on the basis of recommendations from GBD 
collaborators. The rates were standardised according to 
the GBD world population and reported per 
100 000 person-years.17 The method for propagating 
uncertainty in this paper is similar to that used in 
Research in context
Evidence before this study
This study is part of the Global Burden of Diseases, Injuries, and 
Risk Factors Study (GBD), which is the most comprehensive 
effort to date to measure epidemiological levels and trends. 
In its most up-to-date iteration, 359 diseases and injuries; 
282 causes of death; and 84 behavioural, environmental and 
occupational, and metabolic risk factors were studied. 
The International Agency for Research on Cancer generates 
periodically updated estimates for all cancers including 
colorectal cancer in the Global Cancer Incidence, Mortality and 
Prevalence (GLOBOCAN) project. The burden of colorectal 
cancer has been investigated in previous research using 
GLOBOCAN data, but these studies have several limitations. 
The global burden of colorectal cancer is reported in terms of 
incidence and mortality, but important measures such as years 
of life lost, years lived with disability, and disability-adjusted 
life-years are not reported. The measures GLOBOCAN produces 
do not allow for comparability of the burden of disability or 
premature mortality between countries or with other causes. 
The temporal trends in GLOBOCAN estimates begin in 
2002 and have occurred globally at 4-year or 6-year intervals 
with 95% uncertainty intervals provided only for the 
2018 estimates. Using a consistent methodology to produce 
annual estimates dating back to 1990 provides a rich context 
for the burden estimates. Finally, the burden of colorectal 
cancer attributable to risk factors has not previously been 
calculated.
Added value of this study
To our knowledge, this study is the first to report the incidence, 
mortality, and disability from colorectal cancer and its 
attributable risk factors from 1990 to 2017 in 195 countries and 
territories, by age, sex, Socio-demographic Index (a composite 
of sociodemographic factors), and Healthcare Access and Quality 
Index, an indicator of health system performance.
Implications of all the available evidence
Colorectal cancer remains a substantial public health challenge 
across the globe. Age-standardised incidence rates increased in 
most countries from 1990 to 2017, and the age-standardised 
death rate decreased at the global level and decreased 
particularly in countries high on the Socio-demographic Index. 
The burden of colorectal cancer was mainly attributed to dietary 
risks, alcohol use, and smoking. Further research is required to 
better understand the increases in incidence of colorectal cancer 
and to improve prevention, early detection, and treatment of 
this disease.
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previous GBD 2017 papers.4,19 The distribution of every 
step in the computation process is stored in 1000 draws 
that are used for every other step in the process. The 
distributions are characterised from the sampling error 
of data inputs, the uncertainty of the model coefficients, 
MIRs, and age-specific death rates. GBD assumes that 
uncertainty in the MIR is independent of uncertainty in 
the estimated age-specific death rates. Final estimates 
were computed using the mean estimate across 
1000 draws, and the 95% UIs were specified on the basis 
of the 25th and 975th ranked values across all 1000 draws. 
The GBD study is compliant with the Guidelines for 
Accurate and Transparent Health Estimates Reporting 
(GATHER).
Data sources
All cancers coded as C18–C21, D01.0–D01.2, and 
D12–D12.8 in the 10th revision of the International 
Classification of Diseases were considered to be colorectal 
cancer.19 Vital registration (18 857 site-years of data), 
sample vital registration (761 site-years), verbal autopsy 
(660 site-years), and cancer registry (4474 site-years) data 
from GBD 2017 were used in this study.4 Vital registration 
is the system by which governments record the vital 
events of their residents, including causes of death. In 
sample vital registration, vital events are recorded in 
nationally representative cluster samples to estimate 
birth rates, deaths rates, and causes of death for the total 
population in countries where high coverage of vital 
registration is not available. Verbal autopsy is a method 
by which trained interviewers collect information about 
the signs, symptoms, and demo graphic characteristics of 
a recently deceased person from an individual familiar 
with the deceased to determine individuals’ causes of 
death and cause-specific mortality fractions in popu-
lations without a complete vital registration system. 
Finally, a cancer registry gathers data on every person 
with cancer in a defined population, usually comprising 
residents in a well defined geographical region. The 
details on data quality rating for 195 countries and 
territories are provided in the appendix (pp 11–17). More 
detailed information about the data sources used for 
each country can be found on the GBD 2017 Data Input 
Sources Tool website.
Mortality estimates
Mortality data from vital registration, sample vital 
registration, and verbal autopsy were sparse. Therefore, 
incidence data from cancer registries were converted into 
mortality data by modelling the MIRs independently. We 
modelled MIRs using the locations that had both 
incidence and mortality data available for the same year. 
The initial MIR model used a linear-step mixed-effects 
model with logit link functions, as well as the HAQ Index, 
age, and sex as covariates. The resulting estimates were 
then smoothed over space and time, and adjusted with 
spatiotemporal Gaussian process regression.18 We used 
the observed mortality (from vital registration and verbal 
autopsy) and mortality estimates (computed from the 
MIRs and incidence data) as inputs for a CODEm.4 
Country-level covariates used for the CODEm and the 
assumed directions are described in the appendix (p 18). 
We used CODEm to select which predictors produce the 
best fit to the data. We used the CoDCorrect algorithm to 
adjust the sum of predicted single-cause mortalities in an 
age–sex–location–year group to be consistent with the 
results from all-cause mortality estimation.4
Non-fatal estimates
The final mortality estimates were divided by the MIR to 
compute colorectal cancer incidence.19 Colorectal cancer 
prevalence was calculated by estimating 10-year survival 
based on MIRs and adjusting for expected background 
mortality. The cohort members who had survived more 
than 10 years were assumed to be cured, and one of the 
two sequelae were assigned to them: the diagnosis and 
primary therapy phase or the controlled phase. The 
controlled phase included all patients who survived more 
than 10 years and who had finished primary therapy. The 
prevalence for the cohort in which people died during the 
10-year period was categorised into four sequelae 
(appendix p 20). The diagnosis and primary therapy 
phase was defined as 4·0 months, the metastatic phase 
as 9·7 months, and terminal phase as 1 month.22,23 The 
remaining time was assigned to the controlled phase. 
The duration of sequela one (diagnosis and primary 
therapy) described by Allgar and colleagues22 was used 
and 2 months were added to account for the average 
treatment duration. Duration of sequela two (controlled 
phase) was 10 years for the survivors minus the duration 
of the other sequelae. Duration of sequela three 
(metastatic phase) was based on Surveillance, 
Epidemiology, and End Results (SEER) data for median 
survival of patients with stage IV disease. A duration of 
1 month for sequela four (terminal phase) was used for 
all cancers.22
To estimate procedure-related disability for all 
locations by age, sex, and year, we used hospital data on 
the proportion of patients that undergo ostomies (ie, the 
procedure proportion) as our input for a DisMod-MR 
2.1 proportion model.19 We determined through a 
literature review that an average of 58% of all ostomies 
are for colorectal cancer, so we multiplied the all-cause 
ostomies by 0·58.24–26 We applied these procedure 
proportions to the number of incident cases of colorectal 
cancer and multiplied that by the proportion of the 
incident population that had survived for 10 years. This 
process gave us the number of incident cases of 
colorectal cancer that involved an ostomy procedure and 
survived beyond 10 years. We then input these cases 
into DisMod-MR 2.1. This model produced estimates of 
incidence and lifetime prevalent cases of people with 
colorectal cancer-related stomas who have survived 
beyond 10 years.19
See Online for appendix
For the GBD 2017 Data Input 
Sources Tool see http://ghdx.
healthdata.org/gbd-2017/data-
input-sources
For SEER see www.seer.
cancer.gov
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1990 2017 Percentage change in 
age-standardised 
incidence rates, 
1990–2017
Incident cases Age-standardised 
incidence rate (per 
100 000 person-years)
Incident cases Age-standardised 
incidence rate (per 
100 000 person-years)
Global 826 357 
(807 380 to 854 834)
21·2 
(20·7 to 21·9)
1 833 451 
(1 791 865 to 1 873 464)
23·2 
(22·7 to 23·7)
9·5% 
(4·5 to 13·5)
Central Europe, eastern Europe, and central Asia
Central Asia 5534 (5430 to 5645) 11·2 (11·0 to 11·4) 8977 (8558 to 9410) 12·3 (11·8 to 12·9) 10·0% (5·3 to 14·8)
Armenia 418 (397 to 441) 14·7 (14·0 to 15·5) 772 (728 to 815) 18·7 (17·7 to 19·8) 27·1% (18·1 to 36·5)
Azerbaijan 536 (506 to 568) 9·9 (9·3 to 10·4) 1210 (1028 to 1383) 12·9 (11·0 to 14·6) 30·1% (11·6 to 49·0)
Georgia 737 (698 to 779) 11·7 (11·1 to 12·4) 901 (836 to 964) 15·7 (14·6 to 16·8) 34·2% (23·4 to 46·0)
Kazakhstan 2064 (1992 to 2146) 15·5 (15·0 to 16·1) 2773 (2566 to 3009) 16·4 (15·2 to 17·8) 6·2% (–1·9 to 13·6)
Kyrgyzstan 387 (364 to 411) 12·4 (11·7 to 13·2) 372 (344 to 421) 8·5 (7·9 to 9·5) –31·5% (–37·3 to –22·6)
Mongolia 91 (83 to 102) 8·5 (7·7 to 9·4) 183 (158 to 206) 8·2 (7·1 to 9·3) –2·6% (–19·4 to 14·1)
Tajikistan 229 (216 to 242) 7·5 (7·1 to 7·9) 430 (385 to 482) 8·0 (7·2 to 8·9) 6·8% (–4·8 to 18·8)
Turkmenistan 155 (148 to 163) 7·4 (7·1 to 7·8) 353 (325 to 384) 9·6 (8·8 to 10·4) 28·8% (16·4 to 42·3)
Uzbekistan 917 (882 to 953) 7·4 (7·1 to 7·7) 1982 (1757 to 2219) 9·5 (8·4 to 10·6) 28·2% (14·1 to 42·8)
Central Europe 41 719 (41 148 to 42 319) 27·7 (27·3 to 28·1) 72 984 (70 812 to 75 162) 34·6 (33·5 to 35·6) 24·8% (20·8 to 29·0)
Albania 184 (171 to 218) 8·1 (7·5 to 10·0) 454 (371 to 552) 11·2 (9·2 to 13·5) 37·5% (10·6 to 69·3)
Bosnia and Herzegovina 671 (627 to 778) 16·2 (15·2 to 18·9) 1735 (1584 to 1896) 29·4 (27·0 to 32·0) 81·8% (61·7 to 100·4)
Bulgaria 3092 (2983 to 3202) 24·1 (23·3 to 24·9) 5156 (4765 to 5545) 35·5 (32·8 to 38·1) 47·5% (35·6 to 59·5)
Croatia 2211 (2126 to 2297) 34·4 (33·1 to 35·7) 3993 (3720 to 4278) 45·9 (42·9 to 49·2) 33·6% (23·0 to 44·4)
Czech Republic 6800 (6579 to 7013) 48·6 (47·1 to 50·1) 8320 (7750 to 8966) 40·1 (37·4 to 43·2) –17·5% (–23·9 to –10·3)
Hungary 6117 (5932 to 6300) 40·8 (39·6 to 41·9) 8454 (7883 to 9040) 44·7 (41·7 to 47·7) 9·8% (2·1 to 18·0)
Macedonia 304 (284 to 335) 15·9 (14·8 to 17·8) 812 (722 to 914) 24·1 (21·4 to 27·1) 51·6% (26·6 to 74·6)
Montenegro 124 (113 to 136) 19·7 (17·9 to 21·5) 238 (215 to 265) 23·8 (21·6 to 26·6) 21·1% (6·2 to 38·2)
Poland 10 892 (10 582 to 11 200) 24·1 (23·4 to 24·8) 20 482 (19 092 to 22 015) 29·7 (27·7 to 31·8) 23·3% (14·4 to 32·6)
Romania 4736 (4576 to 4913) 16·5 (16·0 to 17·1) 10 989 (10 254 to 11 753) 30·5 (28·5 to 32·6) 84·4% (70·8 to 98·9)
Serbia 3475 (3188 to 3840) 30·1 (27·7 to 33·1) 5971 (5507 to 6494) 38·4 (35·4 to 41·7) 27·5% (14·4 to 41·3)
Slovakia 2275 (2178 to 2372) 37·5 (36·0 to 39·1) 4739 (4289 to 5177) 52·4 (47·5 to 57·1) 39·8% (24·3 to 54·4)
Slovenia 837 (801 to 877) 33·6 (32·2 to 35·1) 1639 (1508 to 1785) 39·4 (36·2 to 43·0) 17·4% (7·3 to 29·1)
Eastern Europe 68 421 (66 610 to 71 088) 23·8 (23·2 to 24·7) 103 116 (100 177 to 106 623) 30·2 (29·3 to 31·2) 26·8% (23·4 to 30·6)
Belarus 2904 (2798 to 2999) 21·9 (21·1 to 22·6) 4478 (4078 to 5121) 28·3 (25·7 to 32·5) 29·1% (17·1 to 47·1)
Estonia 588 (563 to 613) 27·9 (26·8 to 29·1) 929 (801 to 1065) 34·8 (30·1 to 40·2) 24·8% (6·8 to 44·4)
Latvia 892 (862 to 925) 24·2 (23·3 to 25·0) 1205 (1066 to 1360) 29·8 (26·2 to 33·7) 23·2% (7·9 to 40·5)
Lithuania 1061 (1026 to 1098) 22·9 (22·1 to 23·6) 1683 (1558 to 1806) 29·2 (27·1 to 31·4) 27·9% (17·5 to 38·6)
Moldova 981 (941 to 1018) 21·1 (20·2 to 21·9) 1437 (1349 to 1539) 25·2 (23·6 to 26·9) 19·3% (10·8 to 28·5)
Russia 42 907 (41 400 to 45 268) 23·1 (22·3 to 24·4) 69 283 (67 424 to 71 061) 29·9 (29·2 to 30·7) 29·5% (23·5 to 34·9)
Ukraine 19 089 (18 412 to 19 805) 26·0 (25·1 to 26·9) 24 101 (22 571 to 25 877) 31·5 (29·6 to 33·8) 21·5% (13·4 to 30·2)
High income
Australasia 11 968 (11 694 to 12 218) 50·2 (49·1 to 51·2) 22 266 (20 408 to 24 232) 46·4 (42·5 to 50·6) –7·4% (–15·7 to 1·0)
Australia 9497 (9253 to 9741) 47·8 (46·6 to 48·9) 18 429 (16 592 to 20 418) 45·7 (41·2 to 50·8) –4·3% (–14·6 to 6·3)
New Zealand 2472 (2365 to 2589) 62·1 (59·5 to 64·9) 3837 (3562 to 4144) 50·2 (46·6 to 54·2) –19·1% (–25·9 to –12·1)
High-income Asia Pacific 67 498 (66 180 to 68 809) 33·2 (32·6 to 33·9) 183 789 (175 950 to 193 063) 41·9 (40·2 to 44·1) 26·1% (20·8 to 32·1)
Brunei 32 (28 to 38) 31·2 (26·7 to 36·4) 139 (127 to 154) 43·8 (39·8 to 48·6) 40·5% (16·6 to 66·7)
Japan 62 351 (61 081 to 63 664) 36·4 (35·6 to 37·1) 153 905 (146 718 to 161 765) 45·0 (43·1 to 47·3) 23·8% (18·3 to 30·0)
Singapore 778 (751 to 808) 34·1 (32·9 to 35·3) 2394 (2213 to 2622) 34·9 (32·2 to 38·1) 2·4% (–6·3 to 12·4)
South Korea 4337 (4184 to 4495) 14·3 (13·8 to 14·8) 27 351 (24 820 to 30 076) 32·5 (29·5 to 35·7) 127·3% (105·1 to 150·7)
High-income North America 165 322 (163 317 to 167 704) 45·6 (45·0 to 46·2) 234 927 (228 060 to 241 844) 39·1 (37·9 to 40·3) –14·2% (–17·2 to –11·4)
Canada 13 301 (12 833 to 13 790) 40·1 (38·7 to 41·5) 25 661 (23 835 to 27 580) 38·5 (35·8 to 41·4) –3·8% (–11·7 to 4·3)
Greenland 15 (13 to 16) 45·4 (40·4 to 50·3) 25 (23 to 28) 39·0 (35·5 to 42·4) –14·2% (–26·5 to –1·2)
(Table continues on next page)
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1990 2017 Percentage change in 
age-standardised 
incidence rates, 
1990–2017
Incident cases Age-standardised 
incidence rate (per 
100 000 person-years)
Incident cases Age-standardised 
incidence rate (per 
100 000 person-years)
(Continued from previous page)
USA 152 002 (150 137 to 154 241) 46·1 (45·6 to 46·8) 209 237 (203 167 to 215 912) 39·1 (38·0 to 40·4) –15·1% (–18·2 to –12·0)
Southern Latin America 9098 (8881 to 9339) 19·5 (19·1 to 20·1) 20 898 (19 394 to 22 657) 25·5 (23·6 to 27·6) 30·4% (20·2 to 41·5)
Argentina 6650 (6439 to 6875) 20·4 (19·8 to 21·0) 13 927 (12 487 to 15 469) 26·1 (23·4 to 29·0) 28·1% (14·8 to 43·3)
Chile 1341 (1285 to 1396) 13·4 (12·9 to 14·0) 5154 (4626 to 5746) 22·2 (19·9 to 24·8) 65·5% (46·7 to 86·6)
Uruguay 1106 (1067 to 1145) 27·8 (26·8 to 28·7) 1817 (1620 to 2025) 33·3 (29·6 to 37·3) 20·0% (6·1 to 34·5)
Western Europe 220 737 (217 920 to 223 500) 37·3 (36·8 to 37·7) 347 288 (332 898 to 361 454) 38·7 (37·1 to 40·3) 3·8% (–0·6 to 8·1)
Andorra 21 (17 to 26) 36·1 (29·6 to 44·0) 52 (42 to 63) 38·3 (30·8 to 46·1) 6·1% (–14·8 to 28·9)
Austria 4883 (4718 to 5065) 40·8 (39·4 to 42·2) 5592 (5201 to 6011) 31·5 (29·3 to 33·9) –22·6% (–28·6 to –16·3)
Belgium 6258 (6013 to 6521) 39·7 (38·2 to 41·2) 8141 (7518 to 8809) 35·5 (32·7 to 38·4) –10·5% (–18·0 to –2·3)
Cyprus 170 (150 to 197) 19·8 (17·5 to 23·0) 551 (492 to 620) 29·0 (26·0 to 32·6) 46·1% (20·5 to 75·4)
Denmark 2330 (2261 to 2399) 28·4 (27·6 to 29·2) 5175 (4762 to 5593) 45·6 (42·0 to 49·3) 60·5% (47·4 to 74·7)
Finland 1784 (1731 to 1838) 24·7 (23·9 to 25·4) 3437 (3197 to 3725) 28·9 (26·9 to 31·3) 17·3% (7·5 to 27·9)
France 29 412 (28 397 to 30 488) 34·3 (33·1 to 35·5) 45 501 (41 853 to 49 486) 33·0 (30·4 to 36·0) –3·7% (–11·7 to 5·4)
Germany 59 179 (57 557 to 60 958) 45·4 (44·2 to 46·7) 76 179 (68 038 to 84 803) 41·1 (36·7 to 45·8) –9·4% (–19·0 to 0·9)
Greece 2661 (2540 to 2784) 17·3 (16·5 to 18·0) 6556 (6083 to 7025) 27·6 (25·6 to 29·6) 60·1% (46·8 to 73·3)
Iceland 87 (82 to 92) 29·7 (28·0 to 31·5) 169 (157 to 182) 31·7 (29·3 to 34·0) 6·5% (–3·4 to 16·7)
Ireland 1643 (1582 to 1705) 39·7 (38·2 to 41·1) 2948 (2661 to 3280) 40·6 (36·7 to 45·2) 2·5% (–8·2 to 14·0)
Israel 1307 (1251 to 1380) 26·7 (25·6 to 28·1) 3165 (2921 to 3438) 27·9 (25·8 to 30·4) 4·5% (–4·1 to 13·6)
Italy 30 748 (29 557 to 31 888) 34·2 (32·9 to 35·4) 52 228 (48 427 to 56 835) 37·2 (34·3 to 40·4) 8·8% (–0·5 to 18·7)
Luxembourg 233 (221 to 247) 41·8 (39·7 to 44·2) 409 (359 to 475) 42·1 (37·0 to 49·3) 0·9% (–11·7 to 17·5)
Malta 109 (104 to 116) 25·4 (24·1 to 27·0) 306 (281 to 333) 34·4 (31·7 to 37·2) 35·2% (22·9 to 48·4)
Netherlands 8553 (8241 to 8849) 41·9 (40·4 to 43·4) 16 948 (15 727 to 18 222) 50·9 (47·1 to 54·7) 21·3% (11·9 to 31·7)
Norway 2861 (2811 to 2917) 41·7 (40·9 to 42·5) 4556 (4316 to 4796) 48·4 (46·0 to 51·0) 16·2% (9·8 to 22·7)
Portugal 4052 (3901 to 4207) 29·5 (28·5 to 30·6) 9390 (8696 to 10288) 41·4 (38·4 to 45·3) 40·3% (28·5 to 54·8)
Spain 17 169 (16 664 to 17 708) 30·8 (29·9 to 31·7) 41 133 (38 218 to 44 436) 43·4 (40·2 to 47·0) 40·8% (29·2 to 53·7)
Sweden 5106 (4972 to 5255) 33·0 (32·1 to 33·9) 7130 (6693 to 7575) 34·7 (32·7 to 36·8) 5·1% (–1·6 to 12·2)
Switzerland 2227 (2137 to 2321) 20·9 (20·1 to 21·8) 5032 (4597 to 5547) 29·4 (26·9 to 32·5) 40·3% (26·6 to 56·1)
UK 39 729 (39 124 to 40 372) 42·7 (42·1 to 43·4) 52 331 (51 067 to 53 737) 41·7 (40·7 to 42·9) –2·3% (–5·2 to 1·0)
Latin America and Caribbean
Andean Latin America 1770 (1608 to 1997) 8·7 (7·9 to 9·7) 7635 (6901 to 8372) 14·2 (12·9 to 15·6) 64·3% (41·6 to 89·3)
Bolivia 324 (201 to 527) 10·3 (6·5 to 16·5) 1092 (799 to 1460) 13·2 (9·7 to 17·6) 28·0% (–9·2 to 77·0)
Ecuador 415 (400 to 432) 7·7 (7·4 to 8·0) 1954 (1769 to 2160) 13·4 (12·2 to 14·8) 73·8% (56·4 to 93·4)
Peru 1031 (947 to 1121) 8·6 (7·9 to 9·4) 4589 (3917 to 5349) 15·0 (12·8 to 17·5) 73·6% (45·2 to 107·2)
Caribbean 4453 (4299 to 4655) 17·1 (16·5 to 17·8) 11 943 (11 109 to 12 868) 23·5 (21·8 to 25·3) 37·6% (29·2 to 47·0)
Antigua and Barbuda 7 (7 to 8) 13·9 (13·0 to 15·0) 20 (18 to 21) 19·9 (18·2 to 21·7) 42·9% (27·1 to 59·8)
The Bahamas 33 (30 to 35) 20·5 (19·2 to 22·0) 95 (85 to 105) 25·8 (23·2 to 28·6) 25·7% (9·6 to 44·1)
Barbados 66 (62 to 71) 22·0 (20·7 to 23·3) 153 (138 to 168) 31·8 (28·6 to 34·8) 44·6% (28·4 to 61·7)
Belize 7 (7 to 8) 7·7 (7·0 to 8·5) 30 (27 to 32) 11·4 (10·5 to 12·5) 47·6% (29·9 to 65·3)
Bermuda 20 (19 to 22) 32·3 (30·0 to 34·4) 46 (41 to 50) 36·0 (32·4 to 39·6) 11·4% (–1·7 to 28·7)
Cuba 2285 (2210 to 2369) 22·0 (21·2 to 22·7) 5629 (4988 to 6293) 29·9 (26·5 to 33·4) 36·0% (21·3 to 52·9)
Dominica 9 (8 to 10) 12·0 (11·2 to 12·9) 16 (15 to 18) 17·4 (15·9 to 19·1) 44·8% (27·8 to 61·8)
Dominican Republic 283 (260 to 307) 7·4 (6·8 to 8·0) 1277 (1100 to 1467) 13·9 (11·9 to 16·0) 87·7% (57·2 to 120·5)
Grenada 11 (10 to 12) 15·6 (14·6 to 16·6) 29 (27 to 32) 18·7 (17·1 to 20·3) 19·6% (7·5 to 32·1)
Guyana 41 (39 to 44) 10·6 (10·0 to 11·2) 79 (70 to 89) 13·2 (11·7 to 14·8) 23·9% (8·2 to 41·6)
Haiti 333 (236 to 517) 10·7 (7·8 to 16·1) 803 (577 to 1164) 12·8 (9·4 to 18·1) 19·2% (–4·1 to 51·4)
Jamaica 243 (229 to 262) 13·3 (12·5 to 14·2) 639 (538 to 743) 22·0 (18·5 to 25·6) 66·1% (36·5 to 96·9)
(Table continues on next page)
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Puerto Rico 726 (694 to 757) 19·5 (18·7 to 20·3) 2084 (1921 to 2254) 30·4 (28·1 to 32·9) 55·5% (43·2 to 69·2)
Saint Lucia 11 (11 to 12) 12·7 (12·0 to 13·4) 31 (29 to 34) 15·1 (13·9 to 16·4) 18·9% (7·5 to 31·4)
Saint Vincent and the Grenadines 10 (9 to 10) 12·9 (12·1 to 13·9) 23 (21 to 25) 16·5 (15·1 to 18·0) 27·7% (13·9 to 43·0)
Suriname 33 (30 to 35) 12·9 (12·0 to 13·8) 107 (96 to 119) 19·0 (17·1 to 21·0) 46·7% (29·5 to 66·4)
Trinidad and Tobago 158 (150 to 167) 18·6 (17·7 to 19·6) 373 (308 to 447) 20·9 (17·3 to 24·9) 12·4% (–7·2 to 35·7)
Virgin Islands 23 (21 to 25) 27·7 (25·1 to 30·5) 80 (69 to 90) 43·5 (37·6 to 49·1) 57·2% (31·8 to 83·3)
Central Latin America 7618 (7492 to 7774) 8·9 (8·8 to 9·1) 35 294 (33 818 to 36 661) 15·2 (14·6 to 15·8) 70·4% (62·5 to 77·8)
Colombia 2012 (1933 to 2094) 11·4 (10·9 to 11·8) 8683 (7757 to 9798) 16·1 (14·4 to 18·2) 41·5% (25·3 to 60·4)
Costa Rica 267 (255 to 279) 15·1 (14·4 to 15·7) 1397 (1264 to 1518) 28·4 (25·7 to 30·9) 88·8% (69·4 to 108·3)
El Salvador 184 (172 to 203) 6·1 (5·7 to 6·6) 869 (731 to 1022) 15·2 (12·8 to 17·8) 149·8% (105·5 to 197·4)
Guatemala 185 (177 to 193) 5·2 (4·9 to 5·4) 1010 (906 to 1118) 9·3 (8·4 to 10·3) 79·4% (59·3 to 101·3)
Honduras 125 (111 to 140) 5·8 (5·1 to 6·5) 582 (443 to 718) 9·7 (7·4 to 11·9) 67·1% (29·4 to 110·8)
Mexico 3381 (3313 to 3458) 7·7 (7·5 to 7·8) 16 550 (15 933 to 17 026) 14·5 (13·9 to 14·9) 88·9% (80·2 to 95·3)
Nicaragua 115 (105 to 126) 7·0 (6·4 to 7·6) 501 (439 to 573) 10·9 (9·6 to 12·5) 56·8% (34·3 to 82·6)
Panama 194 (184 to 203) 12·8 (12·2 to 13·4) 737 (673 to 802) 18·6 (17·0 to 20·2) 45·0% (31·2 to 59·6)
Venezuela 1155 (1109 to 1204) 11·8 (11·3 to 12·2) 4965 (4272 to 5735) 17·9 (15·4 to 20·5) 52·0% (29·8 to 77·8)
Tropical Latin America 9583 (9343 to 9871) 10·5 (10·3 to 10·8) 37 656 (36 473 to 38 850) 16·2 (15·7 to 16·8) 54·2% (46·9 to 60·5)
Brazil 9426 (9184 to 9708) 10·6 (10·4 to 10·9) 36 934 (35 748 to 38 099) 16·3 (15·8 to 16·8) 53·5% (46·3 to 59·9)
Paraguay 157 (143 to 171) 7·2 (6·6 to 7·9) 722 (599 to 860) 13·9 (11·5 to 16·5) 91·7% (56·2 to 131·7)
North Africa and Middle East
North Africa and Middle East 15 515 (13 256 to 19 992) 8·8 (7·6 to 11·2) 52 224 (49 748 to 54 659) 12·4 (11·8 to 12·9) 39·9% (7·3 to 65·8)
Afghanistan 747 (306 to 1691) 10·6 (4·6 to 23·4) 1458 (806 to 2773) 12·9 (7·7 to 22·9) 21·0% (–10·0 to 101·4)
Algeria 857 (763 to 956) 6·9 (6·1 to 7·7) 2821 (2488 to 3132) 8·6 (7·6 to 9·6) 25·7% (3·0 to 48·8)
Bahrain 22 (20 to 25) 11·6 (10·0 to 13·6) 110 (96 to 126) 11·3 (10·0 to 12·6) –2·8% (–20·8 to 22·0)
Egypt 1476 (1357 to 1618) 4·9 (4·6 to 5·5) 4500 (3742 to 5195) 7·3 (6·1 to 8·4) 48·6% (16·9 to 76·2)
Iran 2280 (1950 to 2824) 8·6 (7·4 to 10·5) 9784 (8702 to 10304) 14·0 (12·5 to 14·7) 63·3% (27·5 to 94·0)
Iraq 631 (505 to 809) 8·1 (6·5 to 10·1) 1309 (1183 to 1430) 5·6 (5·0 to 6·0) –31·1% (–47·4 to –12·1)
Jordan 191 (156 to 230) 12·6 (10·2 to 15·0) 940 (782 to 1095) 15·9 (13·3 to 18·5) 26·8% (–5·6 to 65·9)
Kuwait 63 (59 to 68) 8·2 (7·7 to 8·9) 290 (249 to 344) 10·9 (9·3 to 12·9) 32·9% (15·8 to 58·7)
Lebanon 383 (323 to 449) 17·3 (14·6 to 20·2) 1692 (1404 to 1994) 28·1 (23·4 to 33·2) 62·7% (26·4 to 101·4)
Libya 281 (227 to 357) 14·2 (11·6 to 17·8) 1053 (889 to 1240) 21·8 (18·4 to 25·4) 52·8% (15·2 to 102·0)
Morocco 897 (768 to 1063) 6·2 (5·3 to 7·3) 2754 (2248 to 3298) 8·8 (7·2 to 10·5) 41·8% (3·5 to 85·6)
Oman 53 (42 to 68) 7·5 (5·9 to 9·4) 222 (180 to 265) 10·9 (9·1 to 12·8) 46·3% (2·3 to 95·9)
Palestine 149 (117 to 191) 16·1 (12·7 to 20·5) 432 (387 to 474) 17·0 (15·2 to 18·6) 5·5% (–22·2 to 40·8)
Qatar 19 (15 to 24) 17·1 (14·3 to 20·8) 158 (132 to 189) 17·8 (15·0 to 21·0) 4·1% (–21·0 to 36·4)
Saudi Arabia 438 (339 to 576) 6·7 (5·2 to 8·7) 3000 (2539 to 3528) 16·6 (14·2 to 18·9) 149·2% (76·9 to 242·9)
Sudan 627 (407 to 1087) 6·6 (4·4 to 11·1) 1509 (1111 to 2104) 8·3 (6·3 to 11·4) 25·8% (–11·2 to 81·4)
Syria 384 (318 to 477) 6·9 (5·8 to 8·6) 1237 (1018 to 1501) 9·7 (8·0 to 11·7) 39·5% (2·1 to 79·1)
Tunisia 431 (378 to 499) 8·8 (7·7 to 10·1) 1476 (1164 to 1833) 12·3 (9·7 to 15·2) 40·5% (0·8 to 86·2)
Turkey 5162 (4082 to 6691) 14·0 (11·2 to 18·0) 15 436 (13 838 to 17 433) 17·6 (15·8 to 20·0) 26·1% (–6·9 to 58·6)
United Arab Emirates 60 (43 to 83) 13·3 (9·4 to 18·6) 759 (598 to 940) 19·9 (16·3 to 24·1) 50·3% (–0·1 to 121·4)
Yemen 354 (189 to 634) 6·9 (4·0 to 11·8) 1234 (868 to 1820) 9·5 (6·9 to 13·5) 38·2% (–5·6 to 123·3)
South Asia
South Asia 36 162 (31 934 to 43 729) 6·2 (5·5 to 7·4) 104 958 (93 845 to 113 041) 8·1 (7·2 to 8·7) 31·6% (1·8 to 55·6)
Bangladesh 4935 (4048 to 6317) 9·6 (8·0 to 12·3) 10 188 (8726 to 12 073) 8·4 (7·2 to 10·0) –12·5% (–35·5 to 12·9)
Bhutan 17 (12 to 25) 6·6 (4·9 to 9·7) 48 (36 to 62) 8·1 (6·2 to 10·3) 22·1% (–18·4 to 79·2)
(Table continues on next page)
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India 26 950 (23 572 to 33 017) 5·8 (5·1 to 7·0) 82 775 (74 559 to 89 201) 7·9 (7·1 to 8·6) 37·5% (6·0 to 64·0)
Nepal 547 (373 to 843) 5·8 (4·0 to 8·8) 1438 (1157 to 1841) 7·0 (5·6 to 8·9) 20·1% (–13·0 to 63·7)
Pakistan 3713 (3334 to 4094) 6·4 (5·7 to 7·0) 10 509 (7826 to 12 968) 9·4 (7·0 to 11·4) 47·1% (10·5 to 82·3)
Southeast Asia, east Asia, and Oceania
East Asia 114 366 (107 795 to 125 264) 12·3 (11·6 to 13·5) 462 088 (438 223 to 483 591) 22·8 (21·6 to 23·9) 85·2% (63·9 to 102·6)
China 107 038 (100 408 to 117 587) 12·2 (11·4 to 13·4) 431 951 (408 225 to 452 721) 22·4 (21·2 to 23·5) 84·1% (62·0 to 102·2)
North Korea 2095 (1683 to 2551) 12·2 (9·9 to 14·8) 4483 (3552 to 5524) 14·3 (11·3 to 17·5) 16·8% (–9·7 to 51·5)
Taiwan (province of China) 3327 (3242 to 3418) 19·9 (19·4 to 20·4) 18 209 (17 062 to 19 442) 48·0 (45·1 to 51·3) 141·9% (126·3 to 158·5)
Oceania 308 (252 to 447) 10·0 (8·5 to 14·2) 745 (617 to 1031) 11·2 (9·8 to 14·8) 12·1% (–3·2 to 27·8)
American Samoa 4 (3 to 4) 15·9 (14·1 to 17·6) 8 (7 to 9) 18·5 (16·5 to 20·7) 16·7% (–0·5 to 38·5)
Federated States of Micronesia 6 (5 to 8) 11·9 (9·7 to 15·5) 9 (7 to 12) 13·7 (10·9 to 16·9) 15·3% (–6·7 to 39·9)
Fiji 34 (29 to 41) 9·3 (7·9 to 10·9) 82 (68 to 95) 11·8 (9·8 to 13·5) 26·6% (–0·4 to 57·5)
Guam 16 (14 to 18) 18·8 (16·9 to 21·0) 43 (38 to 47) 23·8 (21·6 to 26·4) 26·5% (7·3 to 50·9)
Kiribati 4 (3 to 4) 9·5 (8·4 to 10·5) 7 (6 to 8) 10·3 (8·5 to 12·2) 9·0% (–14·1 to 33·0)
Marshall Islands 2 (2 to 3) 14·1 (10·6 to 20·0) 6 (4 to 7) 17·2 (13·7 to 22·2) 21·9% (2·0 to 47·8)
Northern Mariana Islands 3 (3 to 4) 16·5 (14·2 to 19·9) 9 (8 to 10) 17·8 (15·7 to 20·0) 7·3% (–12·7 to 28·8)
Papua New Guinea 187 (139 to 298) 9·3 (7·2 to 14·6) 469 (355 to 737) 10·0 (7·9 to 15·3) 8·0% (–11·0 to 31·5)
Samoa 9 (7 to 11) 10·2 (8·3 to 12·9) 15 (12 to 18) 11·2 (9·2 to 13·5) 9·6% (–14·4 to 39·0)
Solomon Islands 11 (9 to 17) 7·9 (6·2 to 11·8) 29 (23 to 38) 9·0 (7·4 to 11·7) 13·8% (–7·9 to 37·3)
Tonga 4 (4 to 5) 7·9 (7·0 to 9·1) 7 (6 to 8) 9·4 (7·9 to 10·9) 19·4% (–6·8 to 46·8)
Vanuatu 8 (6 to 11) 11·5 (8·9 to 16·0) 21 (16 to 28) 12·9 (9·8 to 17·1) 12·5% (–15·1 to 45·0)
Southeast Asia 27 105 (23 553 to 32 801) 10·4 (9·1 to 12·5) 85 149 (80 680 to 90 557) 14·7 (14·0 to 15·6) 40·9% (15·4 to 63·2)
Cambodia 572 (339 to 1013) 12·4 (7·5 to 21·6) 1445 (1086 to 1940) 13·1 (10·0 to 17·4) 5·6% (–25·7 to 56·9)
Indonesia 7946 (6669 to 10 070) 7·8 (6·6 to 9·9) 18 739 (17 443 to 20 172) 9·3 (8·6 to 10·0) 18·0% (–9·8 to 43·7)
Laos 251 (154 to 408) 11·9 (7·5 to 19·1) 488 (377 to 650) 11·7 (9·2 to 15·4) –1·6% (–29·0 to 40·8)
Malaysia 1800 (1555 to 2184) 20·5 (17·5 to 24·7) 6605 (5777 to 7568) 26·9 (23·6 to 30·6) 31·1% (5·5 to 55·9)
Maldives 7 (5 to 12) 7·8 (5·3 to 11·9) 27 (24 to 31) 9·1 (7·9 to 10·2) 15·6% (–31·1 to 78·3)
Mauritius 74 (70 to 78) 9·9 (9·4 to 10·5) 322 (294 to 351) 19·4 (17·6 to 21·1) 95·4% (76·0 to 115·6)
Myanmar 3328 (1899 to 5522) 14·2 (8·3 to 23·3) 6560 (4900 to 9053) 14·9 (11·2 to 20·6) 5·4% (–21·4 to 55·0)
Philippines 2039 (1903 to 2160) 6·5 (6·1 to 6·9) 13 472 (11 799 to 15 373) 18·4 (16·1 to 20·8) 181·9% (145·4 to 227·0)
Sri Lanka 654 (610 to 705) 6·0 (5·6 to 6·4) 2451 (1929 to 2976) 10·1 (8·0 to 12·2) 69·4% (32·7 to 110·5)
Seychelles 9 (8 to 10) 15·0 (13·6 to 17·9) 39 (35 to 42) 36·4 (32·6 to 39·8) 142·4% (84·6 to 176·7)
Thailand 4671 (4283 to 5179) 12·4 (11·3 to 13·7) 15 598 (13 999 to 17 415) 16·0 (14·3 to 17·8) 29·3% (10·2 to 47·1)
Timor-Leste 20 (15 to 32) 7·1 (5·4 to 10·6) 79 (63 to 102) 10·2 (8·1 to 13·0) 43·1% (1·8 to 94·3)
Vietnam 5697 (4925 to 6498) 13·8 (12·0 to 15·8) 19 210 (16 530 to 22 243) 21·0 (18·2 to 24·1) 51·9% (21·3 to 87·3)
Sub-Saharan Africa
Central sub-Saharan Africa 1904 (1499 to 2534) 8·7 (7·2 to 11·1) 4416 (3711 to 5434) 9·2 (7·9 to 10·9) 5·2% (–11·9 to 25·7)
Angola 373 (246 to 563) 9·7 (6·8 to 14·0) 1049 (857 to 1289) 10·3 (8·4 to 12·4) 6·0% (–26·2 to 53·2)
Central African Republic 111 (64 to 180) 9·8 (6·1 to 15·2) 202 (115 to 335) 9·8 (6·1 to 15·4) 0·0% (–20·2 to 24·5)
Congo (Brazzaville) 129 (96 to 171) 12·2 (9·5 to 15·4) 300 (234 to 386) 12·8 (10·3 to 15·7) 5·2% (–18·2 to 38·8)
Democratic Republic of the Congo 1205 (953 to 1563) 8·0 (6·6 to 10·1) 2676 (2098 to 3493) 8·4 (6·8 to 10·5) 4·2% (–15·7 to 29·5)
Equatorial Guinea 19 (11 to 31) 9·9 (6·4 to 15·2) 54 (35 to 78) 12·2 (8·0 to 17·1) 22·1% (–35·7 to 107·4)
Gabon 66 (51 to 88) 12·0 (9·4 to 15·5) 134 (101 to 168) 13·2 (9·9 to 16·3) 10·2% (–21·1 to 42·6)
Eastern sub-Saharan Africa 7703 (6131 to 9924) 10·5 (8·6 to 13·3) 16 007 (14 839 to 17 000) 10·7 (9·9 to 11·3) 1·2% (–20·0 to 26·6)
Burundi 184 (141 to 247) 8·7 (6·7 to 11·4) 328 (258 to 429) 8·4 (6·8 to 10·8) –2·8% (–22·1 to 22·1)
Comoros 24 (19 to 31) 11·8 (9·4 to 15·4) 52 (43 to 64) 12·0 (9·8 to 14·6) 1·9% (–20·9 to 34·3)
(Table continues on next page)
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Following this process, to estimate the sequela-specific 
YLDs, procedure sequelae prevalence and general 
sequela prevalence rates were multiplied by the sequela-
specific disability weight. The disability weights for four 
sequelae and one procedure can be found in the 
appendix (p 19).19 The disability weights ranged from 
0 (perfect health) to 1 (equivalent to death). GBD uses 
different disability weights for the four phases of 
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Djibouti 20 (13 to 30) 13·4 (8·9 to 19·9) 77 (53 to 109) 14·4 (10·2 to 19·9) 7·2% (–25·2 to 60·7)
Eritrea 124 (87 to 180) 13·0 (9·5 to 18·7) 320 (248 to 412) 14·3 (11·4 to 17·9) 9·9% (–20·3 to 58·5)
Ethiopia 2566 (1412 to 3859) 14·1 (8·3 to 20·6) 4375 (3873 to 4821) 11·7 (10·4 to 12·8) –17·1% (–44·2 to 45·3)
Kenya 680 (565 to 832) 8·2 (6·8 to 10·1) 1966 (1754 to 2229) 9·6 (8·6 to 10·9) 17·5% (2·2 to 32·4)
Madagascar 527 (403 to 726) 10·1 (7·7 to 13·7) 1021 (771 to 1385) 10·0 (7·6 to 13·4) –1·1% (–19·1 to 22·1)
Malawi 194 (128 to 235) 5·0 (3·5 to 5·9) 438 (352 to 523) 6·1 (4·9 to 7·2) 22·3% (–5·5 to 79·8)
Mozambique 697 (599 to 803) 12·1 (10·4 to 13·9) 1503 (1236 to 1830) 14·4 (12·1 to 17·3) 19·2% (–9·8 to 55·4)
Rwanda 239 (179 to 322) 8·4 (6·2 to 11·2) 448 (285 to 604) 8·2 (5·3 to 11·0) –2·0% (–25·6 to 28·8)
Somalia 281 (144 to 472) 11·2 (6·4 to 18·3) 766 (495 to 1188) 12·7 (8·4 to 19·4) 13·6% (–17·4 to 72·5)
South Sudan 244 (146 to 383) 10·5 (6·7 to 15·9) 402 (283 to 588) 11·1 (7·8 to 16·0) 5·7% (–22·6 to 52·3)
Tanzania 1055 (805 to 1321) 10·2 (8·2 to 12·7) 2307 (1954 to 2715) 10·1 (8·6 to 11·8) –1·3% (–25·3 to 27·9)
Uganda 504 (430 to 588) 7·7 (6·6 to 9·0) 1263 (1044 to 1499) 9·5 (7·9 to 11·2) 22·1% (–2·8 to 53·2)
Zambia 361 (287 to 444) 13·1 (10·7 to 15·8) 731 (622 to 841) 12·2 (10·4 to 13·9) –7·0% (–30·2 to 21·9)
Southern sub-Saharan Africa 2591 (2398 to 2816) 9·3 (8·5 to 10·2) 6002 (5469 to 6404) 11·1 (10·1 to 11·8) 19·1% (10·4 to 26·8)
Botswana 51 (42 to 61) 9·1 (7·6 to 10·7) 134 (111 to 170) 10·5 (8·8 to 13·0) 15·9% (–10·1 to 44·4)
Lesotho 70 (58 to 95) 7·4 (6·1 to 9·8) 122 (95 to 153) 10·7 (8·4 to 13·3) 43·8% (11·1 to 81·6)
Namibia 56 (46 to 72) 7·8 (6·5 to 10·0) 118 (100 to 139) 8·6 (7·3 to 10·1) 9·8% (–21·3 to 45·5)
South Africa 1989 (1803 to 2212) 9·3 (8·3 to 10·5) 4774 (4223 to 5154) 11·1 (9·8 to 12·0) 18·7% (10·5 to 27·2)
Swaziland (eSwatini) 30 (25 to 39) 10·7 (8·9 to 13·5) 72 (56 to 91) 13·3 (10·5 to 16·4) 24·8% (–6·0 to 59·6)
Zimbabwe 395 (349 to 446) 9·7 (8·6 to 10·9) 782 (667 to 915) 11·7 (10·0 to 13·6) 21·0% (1·3 to 44·7)
Western sub-Saharan Africa 6983 (5677 to 9178) 8·2 (6·7 to 10·7) 15 089 (12 862 to 17 883) 9·0 (7·7 to 10·5) 8·8% (–18·3 to 39·8)
Benin 132 (105 to 159) 6·6 (5·3 to 7·9) 350 (280 to 444) 7·9 (6·4 to 9·9) 20·0% (–4·6 to 53·3)
Burkina Faso 508 (408 to 592) 12·3 (10·1 to 14·3) 1146 (955 to 1366) 13·7 (11·5 to 16·1) 11·2% (–13·0 to 43·3)
Cameroon 365 (308 to 425) 8·5 (7·2 to 9·9) 1015 (746 to 1290) 9·4 (7·0 to 11·9) 11·3% (–13·6 to 37·9)
Cape Verde 9 (8 to 10) 4·0 (3·6 to 4·4) 40 (36 to 44) 8·9 (8·0 to 9·8) 124·9% (95·5 to 160·7)
Chad 182 (141 to 252) 6·5 (5·0 to 8·9) 422 (320 to 564) 8·2 (6·3 to 10·8) 27·1% (5·0 to 54·9)
Côte d’Ivoire 220 (193 to 250) 5·7 (5·0 to 6·4) 554 (438 to 698) 5·8 (4·7 to 7·3) 2·5% (–21·4 to 31·0)
The Gambia 20 (17 to 24) 5·9 (5·0 to 6·9) 60 (43 to 80) 6·6 (4·8 to 8·8) 12·8% (–26·3 to 56·6)
Ghana 484 (397 to 613) 7·9 (6·6 to 9·8) 1384 (1113 to 1656) 9·5 (7·6 to 11·2) 19·5% (–18·0 to 58·4)
Guinea 198 (175 to 221) 6·0 (5·4 to 6·7) 403 (323 to 512) 7·7 (6·2 to 9·7) 28·7% (1·5 to 64·7)
Guinea-Bissau 45 (24 to 72) 11·4 (6·4 to 17·9) 72 (50 to 98) 10·8 (7·8 to 14·5) –5·0% (–29·9 to 37·4)
Liberia 87 (69 to 115) 7·8 (6·2 to 10·2) 164 (122 to 230) 9·0 (6·8 to 12·5) 15·8% (–8·9 to 45·2)
Mali 298 (264 to 339) 7·5 (6·7 to 8·5) 625 (454 to 856) 7·8 (5·7 to 10·6) 3·8% (–26·6 to 44·8)
Mauritania 92 (68 to 126) 9·1 (6·8 to 12·4) 181 (138 to 234) 9·5 (7·3 to 12·2) 4·6% (–20·3 to 44·4)
Niger 183 (127 to 267) 6·7 (4·7 to 9·7) 449 (327 to 650) 6·6 (4·9 to 9·5) –1·0% (–18·3 to 19·3)
Nigeria 3623 (2486 to 5445) 8·5 (5·9 to 12·7) 7096 (5194 to 9621) 9·2 (6·9 to 12·3) 8·5% (–27·9 to 65·9)
São Tomé and Príncipe 6 (5 to 6) 8·4 (7·5 to 9·5) 13 (10 to 18) 13·8 (10·6 to 17·9) 63·1% (22·4 to 115·0)
Senegal 293 (231 to 381) 9·3 (7·3 to 12·0) 564 (438 to 697) 8·3 (6·5 to 10·2) –10·8% (–39·8 to 28·9)
Sierra Leone 158 (113 to 220) 8·2 (5·9 to 11·3) 303 (229 to 403) 9·3 (7·1 to 12·3) 14·1% (–9·6 to 44·1)
Togo 80 (63 to 96) 6·5 (5·2 to 7·9) 247 (190 to 316) 7·7 (6·0 to 9·6) 17·3% (–4·9 to 43·2)
Data in parentheses are 95% uncertainty intervals.
Table: Incident cases of colorectal cancer for both sexes and percentage change in age-standardised rates by location, 1990–2017
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colorectal cancer, but these weights are the same for all 
cancers.
YLLs were calculated by multiplying the estimated 
number of deaths by age with a standard life expectancy 
at that age. Finally, DALYs were calculated by summing 
YLDs and YLLs.
SDI and HAQ Index
We used the GBD 2017 SDI and GBD 2016 HAQ Index to 
determine the association a country’s development level 
had with colorectal cancer age-standardised DALY rates. 
Examining the association of development level (SDI) 
and health system performance (HAQ Index) with 
colorectal cancer burden is important because these 
factors affect the prevalence of cancer risk factors. In 
GBD 2017, the SDI was revised to better reflect the 
development status of each country.4,18–21 The SDI ranges 
from 0 (worst) to 1 (best) and incorporates the total fertility 
rate in women under the age of 25 years, mean education 
for individuals aged 15 years and older, and lag-distributed 
income per person. The HAQ Index reflects the personal 
health-care access and quality for 195 countries and 
territories and was calculated on the basis of amenable 
mortality (ie, deaths from causes that should not occur in 
the presence of effective medical care). The HAQ Index 
ranges from 0 (worst) to 100 (best). Further details on the 
HAQ Index are presented elsewhere.27
Risk factors
We selected risk factors that had evidence of causation 
with colorectal cancer. We extracted the relative risks and 
exposure estimates from all available data sources. We 
calculated a population attributable fraction as the 
proportional reduction in a health outcome that would 
occur if exposure to a risk factor was reduced to the 
theoretical minimum exposure level. We reported the 
proportion of DALYs due to colorectal cancer that were 
attributable to smoking, high body-mass index, high 
fasting plasma glucose, low physical activity, and five 
dietary risks (diets low in calcium, milk, and fibre, and 
diets high in red meat and processed meat). Details on 
definitions of these risk factors and their relative risk for 
colorectal cancer, prevalence of risk factors, and methods 
for quantifying the proportion of the burden of colorectal 
cancer attributable to these risk factors are described 
elsewhere.18 The DALYs due to colorectal cancer that were 
attributable to each risk factor were estimated by 
multiplying the total DALYs for colorectal cancer by the 
population attributable fraction for the risk–outcome 
pair for each age group, sex, location, and year.
Role of the funding source
The funder of the study had no role in study design; the 
collection, analysis, or interpretation of the data; or the 
writing of the report. The corresponding authors had full 
access to the data and had responsibility for final 
submission of the manuscript.
Results
In 2017, there were 1·8 million (95% UI 1·8–1·9) incident 
cases of colorectal cancer, with an age-standardised 
incidence rate of 23·2 (22·7–23·7) per 100 000 person-
years. The age-standardised incidence rate showed 
an increase of 9·5% (4·5–13·5) from 1990 to 2017 
(table). Colorectal cancer also accounted for 896 000 
(876 300–915 700) deaths globally, with an age-standard ised 
death rate of 11·5 (11·3–11·8) per 100 000 person-years 
and a decrease in age-standardised death rates from 1990 
to 2017 (–13·5% [–18·4 to –10·0]; appendix pp 21–29). 
Colorectal cancer was responsible for 19·0 million 
(18·5–19·5) DALYs globally, with an age-standardised rate 
South Asia
Western sub-Saharan Africa
Central sub-Saharan Africa
Eastern sub-Saharan Africa
Oceania
Southern sub-Saharan Africa
North Africa and Middle East
Central Asia
Andean Latin America
Southeast Asia
Central Latin America
Tropical Latin America
East Asia
Caribbean
Southern Latin America
Eastern Europe
Central Europe
Western Europe
High-income North America
High-income Asia Pacific
Australasia
A
0 10 20 30 40 50 60 70
Males
Females
South Asia
Western sub-Saharan Africa
Central sub-Saharan Africa
Eastern sub-Saharan Africa
Oceania
Southern sub-Saharan Africa
North Africa and Middle East
Central Asia
Andean Latin America
Southeast Asia
Central Latin America
Tropical Latin America
East Asia
Caribbean
Southern Latin America
Eastern Europe
Central Europe
Western Europe
High-income North America
High-income Asia Pacific
Australasia
B
0 5 10 15 20 25 30
Age-standardised death rate (per 100 000 person-years)
Age-standardised incidence rate (per 100 000 person-years)
Figure 1: The age-standardised incidence (A) and death (B) rates of colorectal cancer for 21 GBD regions by 
sex, 2017
Error bars indicate 95% uncertainty intervals. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study.
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of 235·7 (229·7–242·0) DALYs per 100 000 person-years. 
The age-standardised DALY rate decreased from 1990 to 
2017 (–14·5% [–20·4 to –10·3]; appendix pp 30–39).
Australasia (46·4 [95% UI 42·5–50·6] per 
100 000 person-years), high-income Asia Pacific (41·9 
[40·2–44·1] per 100 000 person-years), and high-income 
North America (39·1 [37·9–40·3] per 100 000 person-
years) had the highest age-standardised incidence rates 
in 2017. By contrast, south Asia (8·1 [7·2–8·7] per 
100 000 person-years), western sub-Saharan Africa 
(9·0 [7·7–10·5] per 100 000 person-years), and central 
sub-Saharan Africa (9·2 [7·9–10·9] per 100 000 person-
years) had the lowest age-standardised incidence rates in 
2017 (table). In all regions except Andean Latin America, 
the age-standardised incidence rate was higher among 
males than females in 2017 (figure 1A). The age-
standardised death rates in 2017 were highest in central 
Europe (20·9 [20·3–21·6] per 100 000 person-years), 
eastern Europe (16·4 [16·0–16·9] per 100 000 person-
years), and southern Latin America (16·1 [14·9–17·4] per 
100 000 person-years). By contrast, south Asia (7·1 
[6·4–7·6] per 100 000 person-years), north Africa and the 
Middle East (8·0 [7·6–8·3] per 100 000 person-years), and 
central Latin America (8·0 [7·7–8·3] per 100 000 person-
years) had the lowest age-standardised death rates in 
2017 (appendix pp 21–29). The age-standardised death 
rates in 2017 were higher for males in all GBD regions 
(figure 1B).
The percentage change in age-standardised incidence 
rates from 1990 to 2017 differed substantially between the 
GBD regions, with east Asia (85·2% [95% UI 
63·9 to 102·6]), central Latin America (70·4% 
[62·5 to 77·8]), and Andean Latin America (64·3% 
[41·6 to 89·3]) showing the largest increases. By contrast, 
high-income North America (–14·2% [–17·2 to –11·4]) and 
Australasia (–7·4% [–15·7 to 1·0]) showed decreasing 
trends during this period, although the decrease for 
Australasia was not significant (table). The percentage 
change in age-standardised death rates from 1990 
to 2017 also differed between the GBD regions. The largest 
increases were seen in south Asia (20·4% [–6·2 to 42·8]), 
central Latin America (20·4% [15·0 to 25·4]), and tropical 
Latin America (18·2% [12·9 to 22·6]). By contrast, the 
largest decreases during this period were found in 
Australasia (–34·0% [–39·2 to –28·6]), high-income North 
America (–30·0% [–32·2 to –27·8]), and western Europe 
(–26·1% [–29·1 to –23·1]; appendix pp 21–29). Percentage 
change increments in age-standardised incidence rates of 
colorectal cancer from 1990 to 2017 were higher among 
males in most regions except Andean Latin America and 
south Asia (figure 2A). Similarly, percentage change 
increments for colorectal cancer age-standardised death 
rates in this period were highest in males in most regions, 
except for south Asia (figure 2B). In 2017, the highest 
number of incident cases were found in east Asia, western 
Europe, and high-income North America (table; 
appendix p 1). The highest numbers of deaths were in east 
Asia, western Europe, and high-income North America in 
2017 (appendix pp 2, 21–28).
In 2017, the age-standardised incidence rates for 
colorectal cancer were highest in Slovakia (52·4 [95% UI 
47·5–57·1] per 100 000 person-years), the Netherlands 
(50·9 [47·1–54·7] per 100 000 person-years), and New 
Zealand (50·2 [46·6–54·2] per 100 000 person-years). 
The lowest age-standardised rates in 2017 were found in 
Iraq (5·6 [5·0–6·0] per 100 000 person-years), Côte d’Ivoire 
(5·8 [4·7–7·3] per 100 000 person-years), and Malawi 
(6·1 [4·9–7·2] per 100 000 person-years; figure 3A; table). 
In 2017, the age-standardised death rates were highest 
in Greenland (26·5 [24·2–28·8] per 100 000 person-years), 
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Figure 2: The percentage change in age-standardised incidence (A) and death (B) rates of colorectal cancer for 
21 GBD regions by sex, 1990–2017
Error bars indicate 95% uncertainty intervals. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study.
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Hungary (26·1 [24·5–27·8] per 100 000 person-years), and 
Slovakia (24·5 [21·9–26·4] per 100 000 person-years). 
Conversely, Iraq (4·5 [4·1–4·9] per 100 000 person-years), 
Maldives (5·1 [4·4–5·7] per 100 000 person-years), and 
Egypt (5·3 [4·3–6·1] per 100 000 person-years) had the 
lowest age-standardised death rates in 2017 (figure 3B; 
appendix pp 21–29).
The percentage change in age-standardised incidence 
rates from 1990 to 2017 differed substantially between 
countries, with the Philippines (181·9% [95% UI 
145·4 to 227·0]), El Salvador (149·8% [105·5 to 197·4]), 
and Saudi Arabia (149·2% [76·9 to 242·9]) showing 
the largest increases. By contrast, Kyrgyzstan (–31·5% 
[–37·3 to –22·6]), Iraq (–31·1% [–47·4 to –12·1]), and 
Austria (–22·6% [–28·6 to –16·3]) showed the largest 
decreases in age-standardised incidence during this period 
(table). The percentage change in age-standardised death 
rates from 1990 to 2017 also differed between countries. 
The largest increases were seen in the Philippines (139·8% 
[109·4 to 176·2]), Cape Verde (108·5% [80·7 to 143·9]), and 
Seychelles (82·9% [40·7 to 107·9]). By contrast, the largest 
decreases during this period were found in Austria 
(–42·7% [–46·7 to –38·8]), the Czech Republic (–38·3% 
[–42·6 to –33·4]), and Singapore (–37·5% [–42·2 to –31·8]; 
appendix pp 21–29).
Our study found that, in 2017, the incidence rate 
increased in a non-linear manner with increasing age 
and was higher in males than in females across all age 
groups (figure 4). The difference in incidence rates 
between males and females increased with each 
increasing age group up to the ages of 85–89 years, after 
which the gap started to decrease again. The number of 
incident cases was also higher in males than in females 
up to the ages of 80–84 years and peaked at ages 
65–69 years (figure 4). A relatively similar pattern was 
also observed for death rates and death counts 
(appendix p 3). The highest rates of incidence and death 
observed were in the oldest age group (≥95 years) for 
both sexes in 2017. The pattern for DALY rates was 
slightly different, such that the age-standardised DALY 
rate started decreasing after the ages of 80–84 years for 
males and after the ages of 85–89 years for females 
(appendix p 4). The number of DALYs was also higher in 
males than in females up to the ages of 80–84 years, and 
then females had slightly higher numbers of DALYs for 
the older age groups. The number of DALYs followed a 
normal distribution and peaked at ages 65–69 years 
(appendix p 4). Decomposition of the DALY rate into 
YLLs and YLDs showed that YLLs were the primary 
contributor to DALYs, with the 2017 YLL rate peaking at 
the ages of 80–84 years (appendix p 5).
Figure 5 presents the global and regional-level observed 
age-standardised DALY rates from 1990 to 2017 versus 
the expected level based only on the SDI values of the 
global regions. The expected pattern was non-linear in 
nature, peaking at an SDI value of approximately 0·75, 
before decreasing with increasing SDI values. However, 
there were large regional differences. Australasia, central 
Europe, western Europe, and high-income North 
America showed the largest decreases in observed age-
standardised DALY rates with increases in SDI value, 
whereas the Caribbean and central Latin American 
regions showed increases in observed age-standardised 
DALY rates with increasing SDI value. The observed age-
standardised DALY rate for some regions, such as 
southern sub-Saharan Africa, initially increased and then 
decreased with an improvement in SDI value over time. 
At the global level, the age-standardised DALY rate 
dropped below the expected level for 2015–17.
Figure 6 shows the national-level observed age-
standardised DALY rates and their association with the 
SDI and HAQ Index. The expected patterns were non-
linear in nature, peaking at an SDI value of approximately 
0·81 and HAQ Index value of approximately 84, before 
decreasing with increasing SDI and HAQ Index values. 
However, there were large national differences. Several 
countries, including Hungary, Greenland, Slovakia, 
Serbia, and Brunei, had a higher than expected age-
standardised DALY rate, whereas others, such as Iraq, 
Maldives, Sri Lanka, Kuwait, and Oman, had much lower 
than expected age-standardised DALY rates based only 
on the SDI. This pattern was also observed based on the 
HAQ Index.
Although the proportions of age-standardised DALYs 
that were attributable to colorectal cancer risk factors 
differed in the GBD regions, diet low in calcium (20·5% 
[95% UI 12·9–28·9]), alcohol use (15·2% [12·1–18·3]), 
and diet low in milk (14·3% [5·1–24·8]) had the three 
highest percentages of attributable age-standardised 
DALYs for both sexes globally (figure 7; appendix p 11). 
This global pattern was different in males and females: 
alcohol use (21·5% [17·4–25·9]), diet low in calcium 
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(19·8% [12·3–28·2]), and smoking (19·2% [12·8–25·3]) 
were the risk factors that contributed most to age-
standardised DALYs in males, whereas diets low in 
calcium (21·3% [13·7–29·9]), milk (14·4% [5·1–24·0]), 
and fibre (12·5% [6·6–19·3]) were the risk factors that 
contributed most to age-standardised DALYs in females 
(appendix pp 6–7). The percentage of DALYs attributable 
to colorectal cancer risk factors also differed across age 
groups, especially for alcohol use, smoking, and high 
fasting plasma glucose. The highest percentage of global 
attributable DALYs were in the 55–59 years age group for 
alcohol use, 65–69 years age group for smoking, and 
85–89 years age group for high fasting plasma glucose 
for both sexes combined (appendix p 8). The sex-specific 
estimates of global DALYs attributable to studied risk 
factors by age are reported in appendix (pp 9–10).
Discussion
From 1990 to 2017, the age-standardised incidence rates 
of colorectal cancer increased globally, with substantial 
regional and national heterogeneity. By contrast, the age-
standardised death and DALY rates decreased across the 
study period. On the basis of our DALY estimates, 
colorectal cancer is the 36th leading cause of disease 
burden globally for 2017, and is the fourth leading cause 
of cancer burden, behind only lung cancer, liver cancer, 
and stomach cancer.
The most recent GLOBOCAN report3 in 2018 estimated 
that there were 1 800 977 incident cases and 861 663 deaths 
from colorectal cancer, which are relatively consistent with 
our 2017 estimates (1 833 451 [95% UI 1 791 865–1 873 464] 
incident cases and 896 040 [876 279–915 720] deaths). 
Similar to the GLOBOCAN report,3 we found that the 
highest age-standardised incidence rates in 2017 were in 
Australasia, high-income Asia Pacific, and high-income 
North America, and the highest age-standardised death 
rates were found in central Europe, eastern Europe, and 
southern Latin America.
We also investigated heterogeneous trends in age-
standardised incidence, death, and DALY rates from 
1990 to 2017 at the national level. Most countries showed 
an increase in the age-standardised incidence rate of 
colorectal cancer during 1990–2017, such that only 
Australasia and high-income North America experienced 
a decrease in age-standardised incidence rate at the 
regional level. One potential explanation for this global 
increase in age-standardised incidence is that the 
introduction of screening tests might have led to 
increased detection and thus increased incidence, but 
this increase might be short-lived because of the removal 
of precancerous polyps during colonoscopies.5 Similarly, 
in countries where screening programmes were 
established two or three decades ago, reductions in death 
rates were observed that support the benefits attributable 
to screening interventions.28 Improving survival by 
adopting the best practices in cancer treatment and 
management can also lead to reduced death rates. On the 
basis of the data from high-income countries, several 
factors might have contributed to the decrease in the 
number of deaths due to colorectal cancer, such as 
enhanced access to screening colonoscopy and early 
stage detection, as well as improved surgical techniques, 
radiotherapy, chemotherapy, targeted therapy, and 
palliative care.29–32 Key interventions to decrease deaths 
from colorectal cancer include the removal of polyps and 
early detection interventions, such as colonoscopy, 
flexible sigmoidoscopy, faecal occult blood testing, and 
faecal immunochemical testing.
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Previous research has investigated the association 
between a country’s development level and the incidence 
and mortality rates of colorectal cancer, using the Human 
Development Index.7 Because one of the components of 
the Human Development Index is health related, it is not 
optimal to use this index when comparing the health 
outcomes of countries. To avoid this problem, we used 
the SDI, which does not contain any health-related 
measures. Our analysis of the association between the 
SDI and age-standardised DALY rate of colorectal cancer 
produced results that have not been previously reported. 
In some regions, such as Australasia and central Europe, 
the age-standardised DALY rates were higher than 
expected from 1990 to 2017, whereas in other regions 
they were lower than expected, such as in central Latin 
America and south Asia. Several regions also fluctuated 
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Figure 6: Age-standardised DALY rates of colorectal cancer for 195 countries and territories by SDI and HAQ Index, 2017
(A) Age-standardised DALY rates of colorectal cancer by 195 countries and the HAQ Index, 2016. (B) Expected values are shown as the black line. DALY=disability-adjusted life-year. 
HAQ Index=Healthcare Access and Quality Index. SDI=Socio-demographic Index.
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between higher and lower than expected age-standardised 
DALY rates during the study period. Therefore, regional 
trends in age-standardised rates of deaths, DALYs, and 
incidence should not just be considered in isolation. 
Instead, their observed rates should be compared with 
their expected rates to determine whether regions have 
managed colorectal cancer better or worse than expected. 
Additionally, dividing regions or countries into developed 
and undeveloped regions to evaluate the association 
between development and colorectal cancer burden 
might be an oversimplification, since the findings from 
this study suggest that the association is complex and 
non-linear in nature. Furthermore, at the national level, 
age-standardised DALY rates of countries on both ends 
of the SDI range were at higher than expected levels 
based on the SDI, so countries at all development levels 
need to enhance their prevention programmes.
Our report indicates that the colorectal cancer burden 
attributable to risk factors is different in males and 
females, and this difference should be considered 
in national policy makers’ prevention programmes. 
Alcohol use, smoking, and diets low in calcium, milk, 
and fibre had considerable attributable colorectal cancer 
burden in males. By contrast, dietary risks, but not 
alcohol use or smoking, were found to have considerable 
attributable burden in females. The results of this study 
highlight the role of certain dietary risk factors, which are 
responsible for a greater burden than smoking or alcohol 
use globally. Specifically, diet low in calcium has been 
previously described as a risk factor for colorectal cancer.33 
However, the large burden attributable to this dietary risk 
factor has not been described before at the global level. 
This large burden attributable to a diet low in calcium is 
likely due in part to the high prevalence of this risk factor. 
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Figure 7: Percentage of age-standardised DALYs due to colorectal cancer attributable to risk factors for 21 GBD regions, both sexes, 2017
DALY=disability-adjusted life-year. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study.
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The results of our study underscore the importance of 
improving diet through public health interventions.
A previous study showed that alcohol use is responsible 
for nearly 10% of global deaths in the population aged 
15–49 years and will lead to remarkable health loss in the 
absence of appropriate policy action.34 The same study 
also reported that the safest level of alcohol consumption 
is zero, which is in contrast to current health guidelines.34 
Decreasing population-level alcohol consumption should 
be considered in prevention strategies to effectively 
minimise the corresponding health loss.34
Smoking is another important risk factor. The global 
prevalence of smoking has decreased by 28% in males 
and 34% in females since 1990.18 Taxation, advertising 
bans, and educational programmes about smoking and 
its toll on health are suggested as strategies to decrease 
smoking prevalence more substantially.18
Diets low in calcium, milk, and fibre should also be 
addressed in colorectal cancer prevention strategies 
along with addressing low physical activity. To improve 
diet, increase physical activity, and reduce smoking, 
the American Heart Association suggests following 
population-based approaches, such as media and educat-
ional campaigns; labelling and consumer infor mation; 
taxation, subsidies, and other economic incentives; 
school and workplace approaches; local environmental 
changes; and direct restrictions and mandates.35
Our findings indicate that although high body-mass 
index was not among the top three risk factors for 
attributable DALYs, it is an important risk factor that has 
a higher attributable percentage of DALYs due to 
colorectal cancer in males than in females. One study 
showed that the prevalence of obesity has doubled in 
more than 70 countries and has continuously increased 
in most other countries since 1980.36 Effective prevention 
programmes are needed to decrease exposure to this 
important risk factor through appropriate strategies, 
such as restricting the advertisement of unhealthy foods, 
using taxation to reduce consumption of unhealthy 
foods, providing subsidies to increase intake of healthy 
foods, and using supply-chain incentives to increase the 
production of healthy foods.37 Fasting plasma glucose can 
also be controlled mainly through physical activity and 
healthy diets.38
This study had several limitations, including the fact 
that some of the variations in age-standardised incidence 
and mortality rates might be due to detection biases as 
well as changes in screening protocols. For example, the 
low age-standardised incidence and death rates in Iraq 
might be due to low detection rates. In addition, a major 
limitation of cancer burden research is the scarcity of 
data for many countries. Although different data sources, 
such as cancer registries, vital registration systems, and 
verbal autopsies, are used to produce cancer estimates, 
some countries do not have any of these sources available 
so their estimates are based on predictive covariates or 
trends from neighbouring countries. Moreover, estimates 
for the most recent years are usually based on past trends 
and covariates because there is a lag in data availability. 
As GBD is an iterative study, additional data sources for 
different locations will be added in future rounds and 
make the estimates more data driven, particularly in 
data-sparse locations.
This study found large country and regional variations 
in the burden of colorectal cancer in 2017. Whereas age-
standardised incidence rates increased in most countries 
and territories over the measurement period, age-
standardised death rates decreased at the global level, 
and in particular in high SDI countries, possibly due to 
fast improvement in diagnostics and interventions in 
these countries. Further research is required to expand 
our knowledge of additional factors associated with 
colorectal cancer incidence and to improve early detection 
and treatment of this disease, especially in developing 
countries. Clearly, colorectal cancer remains a substantial 
public health challenge across the globe. The results of 
GBD 2017 can be valuable for policy makers to implement 
cost-effective interventions and address modifiable risk 
factors and for researchers to design and carry out further 
research on proper modalities for prevention, early 
detection, and treatment of colorectal cancer.
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